ValueQ4, 24Q4, 25TTMSelling/general/admin expenses———Research & development———Operating income———Non-Operating Income, Total———Interest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses———Unusual income/expense———Pretax income———Equity in earnings———Taxes———Non-controlling/minority interest———After tax other income/expense———Net income before discontinued operations———Discontinued operations———Net income———Dilution adjustment———Preferred dividends———Diluted net income available to common stockholders———Basic earnings per share (Basic EPS)———Diluted earnings per share (Diluted EPS)———Average basic shares outstanding———Diluted shares outstanding———EBITDA———EBIT———Cost of revenue———Other cost of goods sold———Depreciation & amortization (cash flow)———
Fresenius Medical Care AG American Depositary Shares (Each repr
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes.